In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific AntibodyNational Institutes of Health (NIH) | (.gov) (EUA) · 23:37 InvestigaçãoEUA
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MDThe American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAA single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Sunday, November 15
Why Multiple Myeloma’s Standard of Care Could Change Again Within a YearCancerNetwork (EUA) · 18:05 TratamentosEUACancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Saturday, November 14
Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026Oncodaily (EUA) · 18:15 Acesso e saúde públicaEUALuciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026 / American Society of Hematology (ASH), ASH 2026, cancer care, Cancer research,
Friday, November 13
REMS Certification and Team-Wide Training for Bispecific Administration in Multiple MyelomaCancerNetwork (EUA) · 15:05 Acesso e saúde públicaEUARalph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed MyelomaCancerNetwork (EUA) · 13:08 Acesso e saúde públicaEUASaad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 13:00 TratamentosEUAMy Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma | OncLive Insights | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Thursday, November 12th
Referral Before Salvage Therapy Keeps CAR T an Option in MyelomaTargeted Onc (EUA) · 22:08 TratamentosEUADuring a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Impressive Results of Trispecific Antibody in Myeloma Presented at EHA 2025 CongressTargeted Onc (EUA) · 22:00 InvestigaçãoEUARecent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.
How Etentamig Stands Out From Other BCMA BispecificsTargeted Onc (EUA) · 22:00 TratamentosEUAPeter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…
What Sustained MRD Negativity Can Settle About Stopping Myeloma MaintenanceCancerNetwork (EUA) · 21:08 InvestigaçãoEUASaad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
CELMoDs as Holding and Bridging Therapy in Multiple MyelomaCancerNetwork (EUA) · 15:43 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.
Lymphoma, Myeloma & Prostate CancerCure Today (EUA) · 15:00 Acesso e saúde públicaEUAFDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer.
EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple MyelomaCancerNetwork (EUA) · 13:13 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple MyelomaCancerNetwork (EUA) · 13:13 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
- FDA Approval of Iberdomide Marks Historic Milestone in Multiple MyelomaCleveland Clinic (EUA) · 06:25 Acesso e saúde públicaEUA
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
Wednesday, 11/11
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma CohortCancerNetwork (EUA) · 20:08 TratamentosEUAIn a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Mehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026Oncodaily (EUA) · 19:13 InvestigaçãoEUAMehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026 / ASH 2026, cancer care, Cancer research, Hematology, Mehak Trehan, Myeloma, OncoDaily
Tuesday, November 10
European Commission Expands Melflufen Label to Third-Line Multiple MyelomaCancerNetwork (EUA) · 17:38 Acesso e saúde públicaEUAData from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
Monday, November 9th
Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaOncLive (EUA) · 21:41 TratamentosEUAThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Diagnosis of Multiple Myeloma Through an Atypical Serum Protein Electrophoresis Profile: A Case ReportCureus (EUA) · 20:01 OutrasEUA
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Friday, November 6th
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Wednesday, 11/04
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)Karyopharm (EUA) · 14:04 Doentes e associaçõesEUA– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026...
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
Myeloma's Gray Zones: Sequencing, Oral Therapy, and FrailtyOncology Nursing News (EUA) · 08:00 Acesso e saúde públicaEUAAt the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.
CD38-Targeted Immuno-PET Helps Detect Active Multiple MyelomaCancerNetwork (EUA) · 08:00 Doentes e associaçõesEUAIn a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Tuesday, November 3rd
CELMoD Mechanisms and Immune Function in Multiple MyelomaCancerNetwork (EUA) · 15:19 OutrasEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith introduce cereblon E3 ligase modulators (CELMoDs) and discuss their dual activity in multiple myeloma.
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUACommunity hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
Evidence Supporting MRD Negativity as a Prognostic and Regulatory Endpoint in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael asks Dr. Scott Goldsmith to explain the evidence supporting the use of minimal residual disease (MRD) negativity as an endpoint for regulatory decision-making in multiple myeloma.
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUAFaculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
MRD Negativity and Its Clinical Significance in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael, Dr. Paul Richardson, and Dr. Scott Goldsmith introduce the relationship between minimal residual disease (MRD) negativity and cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting the role of MRD-negative complete response as an emerging regulatory endpoint.
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple MyelomaCancerNetwork (EUA) · 08:00 Acesso e saúde públicaEUAJoshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Imaging the Invisible: A New Precision Approach to Detecting Multiple MyelomaUniversity of Miami (EUA) · 08:00 InvestigaçãoEUAA phase 2 Sylvester trial found that CD38-targeted immunoPET can reveal active multiple myeloma missed by standard PET/CT.
Monday, 02/11
Frontline Treatment in Multiple Myeloma Is ChangingMedPage Today (EUA) · 08:00 TratamentosEUAExperts discuss the broader use of four-drug regimens and whether treatment can be shortened
Sunday, November 1st
Myeloma Is Many Diseases, and Treatment Must Reflect ThatThe American Journal of Managed Care (EUA) · 07:00 TratamentosEUANikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.
Thursday, October 29th
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?CancerNetwork (EUA) · 17:09 TratamentosEUA“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Multiple myeloma: Cancer patient with 12 tumors finds hope as treatments advancefirstcoastnews.com (EUA) · 07:00 Doentes e associaçõesEUA
